{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:57:33Z","timestamp":1784613453423,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00210-024-03224-2","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T09:02:33Z","timestamp":1720861353000},"page":"10191-10201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a double-blind randomized controlled trial"],"prefix":"10.1007","volume":"397","author":[{"given":"Farshad","family":"Abedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Ghavami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Heidari-Bakavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Jomezadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Tayyebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"key":"3224_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119440","volume":"276","author":"MA Azam","year":"2021","unstructured":"Azam MA, Chakraborty P, Si D, Du B, Mass\u00e9 S, Lai PF, Ha AC, Nanthakumar K (2021) Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci 276:119440","journal-title":"Life Sci"},{"key":"3224_CR2","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42:3727\u20133738","journal-title":"Eur Heart J"},{"key":"3224_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, Myerburg RJ, Goldberger JJ (2021) Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm 18:1098\u20131105","journal-title":"Heart Rhythm"},{"key":"3224_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s13300-020-00924-9","volume":"11","author":"S Fujiki","year":"2020","unstructured":"Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J (2020) Placebo-controlled, double-blind study of empagliflozin (EMPA) and implantable cardioverter-defibrillator (EMPA-ICD) in patients with type 2 diabetes (T2DM): rationale and design. Diabetes Ther 11:2739\u20132755","journal-title":"Diabetes Ther"},{"key":"3224_CR5","unstructured":"Ghzally Y, Mahajan K (2023) Implantable Defibrillator. StatPearls Publishing, Treasure Island (FL). https:\/\/europepmc.org\/article\/nbk\/nbk459196. Accessed 31 Oct 2017"},{"key":"3224_CR6","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:e263\u2013e421","journal-title":"J Am Coll Cardiol"},{"key":"3224_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.898718","volume":"13","author":"Y Jing","year":"2022","unstructured":"Jing Y, Yang R, Chen W, Ye Q (2022) Anti-arrhythmic effects of sodium-glucose co-transporter 2 inhibitors. Front Pharmacol 13:898718","journal-title":"Front Pharmacol"},{"key":"3224_CR8","doi-asserted-by":"crossref","unstructured":"Khanna VK, Khanna VK (2016) Implantable cardioverter defibrillators. Implantable Medical Electronics: Prosthetics, Drug Delivery, and Health Monitoring 293\u2013307","DOI":"10.1007\/978-3-319-25448-7_15"},{"key":"3224_CR9","doi-asserted-by":"crossref","unstructured":"Kheiri B, Barbarawi M, Zayed Y, Hicks M, Osman M, Rashdan L, Kyi HH, Bachuwa G, Hassan M, Stecker EC (2019) Antiarrhythmic drugs or catheter ablation in the management of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Circ: Arrhythm Electrophysiol 12:e007600","DOI":"10.1161\/CIRCEP.119.007600"},{"key":"3224_CR10","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3390\/ijms23031678","volume":"23","author":"E Kolesnik","year":"2022","unstructured":"Kolesnik E, Scherr D, Rohrer U, Benedikt M, Manninger M, Sourij H, von Lewinski D (2022) SGLT2 inhibitors and their antiarrhythmic properties. Int J Mol Sci 23:1678","journal-title":"Int J Mol Sci"},{"key":"3224_CR11","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1097\/MJT.0000000000000928","volume":"26","author":"AH Malik","year":"2019","unstructured":"Malik AH, Aronow WS (2019) Prevention of recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators\u2014a network meta-analysis. Am J Ther 26:e469\u2013e480","journal-title":"Am J Ther"},{"key":"3224_CR12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"3224_CR13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"3224_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/11317980-000000000-00000","volume":"9","author":"K Noyes","year":"2009","unstructured":"Noyes K, Corona E, Veazie P, Dick AW, Zhao H, Moss AJ (2009) Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. Am J Cardiovasc Drugs 9:393\u2013400","journal-title":"Am J Cardiovasc Drugs"},{"key":"3224_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","volume":"119","author":"A Paasche","year":"2024","unstructured":"Paasche A, Wiedmann F, Kraft M, Seibertz F, Herlt V, Blochberger PL, J\u00e1vorszky N, Beck M, Weirauch L, Seeger T (2024) Acute antiarrhythmic effects of SGLT2 inhibitors\u2013dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol 119:93\u2013112","journal-title":"Basic Res Cardiol"},{"key":"3224_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424","journal-title":"N Engl J Med"},{"key":"3224_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.hrtlng.2012.08.006","volume":"42","author":"SM Schulz","year":"2013","unstructured":"Schulz SM, Massa C, Grzbiela A, Dengler W, Wiedemann G, Pauli P (2013) Implantable cardioverter defibrillator shocks are prospective predictors of anxiety. Heart Lung 42:105\u2013111","journal-title":"Heart Lung"},{"key":"3224_CR18","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.1038\/s41598-023-35944-5","volume":"13","author":"D Silva dos Santos","year":"2023","unstructured":"Silva dos Santos D, Tura\u00e7a LT, Coutinho KCdS, Barbosa RAQ, Polidoro JZ, Kasai-Brunswick TH, Campos de Carvalho AC, Girardi ACC (2023) Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Sci Rep 13:8689","journal-title":"Sci Rep"},{"key":"3224_CR19","unstructured":"Stiles M (2019) Implantable cardioverter-defibrillators: Optimal programming. Up to Date"},{"key":"3224_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255\u2013270","journal-title":"Annu Rev Med"},{"key":"3224_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ahj.2022.01.008","volume":"246","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, Oulhaj A, Alber H, Gwechenberger M, Martinek M, Seidl S, Moertl D (2022) Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial)\u2013a phase III study. Am Heart J 246:152\u2013160","journal-title":"Am Heart J"},{"key":"3224_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.915455","volume":"9","author":"J Wu","year":"2022","unstructured":"Wu J, Liu Y, Wei X, Zhang X, Ye Y, Li W, Su X (2022) Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: a mini review. Front Cardiovasc Med 9:915455","journal-title":"Front Cardiovasc Med"},{"key":"3224_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacc.2018.04.086","volume":"72","author":"W Zareba","year":"2018","unstructured":"Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW, Pyykkonen K, McNitt S, Oakes D, Feng C (2018) Ranolazine in high-risk patients with implanted cardioverter-defibrillators: the RAID trial. J Am Coll Cardiol 72:636\u2013645","journal-title":"J Am Coll Cardiol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03224-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:09:51Z","timestamp":1732172991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03224-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03224-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local Ethics Committee of Mashhad University of Medical Sciences (MUMS) approved the study protocol (reference number: IR.MUMS.REC.1401.052) and registered it on the Iranian registry of clinical trials as IRCT20120520009801N7 (approval date: June 11, 2022). All participants were explained and informed of the protocol of the study and signed written consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}